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Prostanoid activity was correlated with the hemody- 
namic effects of protamine sulfate reversal of heparin 
in 24 dogs undergoing three different pretreatment reg- 
imens: Group I (n = 8) received saline, Group II (n = 8) 
received the thromboxane synthetase inhibitor 
U63,557A (30 mg/kg), and Group III (n = 8) received 
indomethacin (10 mg/kg). Pretreatment substances 
were administered as 5-min intravenous infusions 20 
min before anticoagulation with intravenous heparin 
(150 IU/kg). Protamine sulfate (1.5 mg/kg) was subse- 
quently given as a lo-set intravenous infusion 30 min 
after heparin had been administered. Hemodynamic 
data, as well as prostacyclin (PGI,) and thromboxane 
(TxA,) activity in aortic, venous, and pulmonary ar- 
tery blood samples, were assessed over a 30-min time 
period following protamine administration. Group III 
indomethacin pretreatment provided the most protec- 
tion from declines in blood pressure, heart rate, cardiac 
output, venous oxygen saturation, oxygen consump- 
tion, and elevations in pulmonary pressures and was 
accompanied with actual declines in PGI,. Group II 
U63,557A pretreatment was associated with the most 
severe hemodynamic changes and the greatest increase 
in PGI, (+576%). Elevated PGI, correlated with hypo- 
tension at 1 and 3 min (P -=c O.Ol), as well as pulmonary 
artery pressure declines at all times following prota- 
mine reversal. TxA, changes did not correlate with he- 
modynamic changes. Protamine’s adverse hemody- 
namic responses were attenuated with cyelooxygenase 
blockade by indomethacin, but were worsened with se- 
lective TxA, blockade with U63,557A. Excess aracha- 
donic acid precursors in the latter setting may increase 
PGIz production. This study, for the first time, raises 
the possibility that PGI, contributes to the adverse ef- 
fects accompanying protamine reversal of heparin anti- 
coagulation. 0 1991 Academic Press, Inc. 
INTRODUCTION 
Protamine sulfate reversal of heparin anticoagulation 
in laboratory studies as well as in clinical practice is 
1 To whom reprint requests should be addressed at University Hos- 
pital, 2210 THCC, 1500 East Medical Center Drive, Ann Arbor, MI 
48109-0329. 
known to cause systemic hypotension, bradycardia, pul- 
monary artery hypotension or hypertension, thrombo- 
cytopenia, leukopenia, and declines in oxygen consump- 
tion. Increased thromboxane and prostacyclin activity 
has been reported after protamine administration in a 
porcine experimental model, and indomethacin has been 
reported to lessen many of the protamine-related hemo- 
dynamic responses [l-3]. The present investigation was 
designed to assess contributions of the arachidonic acid 
pathway to the effects of protamine reversal of heparin 
anticoagulation in an established canine experimental 
model and to specifically define the role of a thrombox- 
ane synthetase inhibitor and a cyclooxygenase inhibitor 
on usual protamine-related phenomenon. 
METHODS 
Twenty-four adult mongrel dogs, mean weight 22.5 kg, 
were anesthetized with pentobarbital sodium 30 mg/kg, 
mechanically ventilated to maintain arterial blood gases 
within physiologic range, and hydrated with lactated 
Ringers solution as a 20 ml/kg bolus followed by a con- 
tinuous infusion of 10 ml/kg/hr for the duration of the 
experiment. Three pretreatment regimens were investi- 
gated. Group I control dogs (n = 8) received intravenous 
infusions of saline, Group II dogs (n = 8) received the 
specific thromboxane synthetase inhibitor U63,557A 
(Upjohn, Kalamazoo, MI) 30 mg/kg intravenously over 
5 min, and Group III dogs (n = 8) received indomethacin 
(Spectrum Chemical, Gardenia, CA) 10 mg/kg intrave- 
nously over 5 min. Twenty minutes following comple- 
tion of the pretreatment infusions, animals were antico- 
agulated with intravenous administration of beef-lung 
heparin, 150 IU/kg. Thirty minutes later protamine sul- 
fate was administered as a bolus, 1.5 mg/kg over 10 set 
(Fig. 1). 
Oxygen saturations were assessed continuously using 
Oximetric Swan-Ganz catheters (Oximetrix, Mountain 
View, CA). Measurements included systemic mixed ve- 
nous saturation (S,O,) by a catheter inserted in the pul- 
monary artery using a femoral vein approach, systemic 
arterial saturation (S,O,) by a catheter inserted into the 
abdominal aorta using a femoral artery approach, and 
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FIG. 1. Experimental protocol. 
jugular venous saturation (SO, jugular) by way of a 
catheter inserted into an external jugular vein. 
Hemodynamic measurements included systemic 
mean arterial blood pressure, pulmonary artery systolic 
and diastolic pressure, and heart rate. Carotid artery 
flow was measured by an electromagnetic square-wave 
flow meter (Carolina Instruments, King, NC). Cardiac 
output (CO) was determined by thermodilution tech- 
nique (Abbott Critical Care, Abbott Park, IL). Systemic 
oxygen consumption (VO,) was calculated using 
the Fick equation VO, = CO X hemoglobin X 1.34 (S,O, 
- SO,). Cerebral oxygen consumption was similarly ap- 
proximated as VO, cerebral = carotid flow X hemoglobin 
X 1.34 (S,O, - $0, jugular), with recognition that S,O, 
jugular also includes cranial-facial venous return. All 
animals underwent a left lateral thoracotomy and place- 
ment of a left atria1 catheter for blood sampling. 
Hemodynamic measurements were made at 15-set in- 
tervals for 1 min prior to protamine reversal of heparin 
anticoagulation, at 15-set intervals for the first 3 postre- 
versa1 min, and subsequently at 5, 10, 20, and 30 min 
postreversal. Cardiac outputs were measured as rapidly 
as possible, such that one measurement was made ap- 
proximately every 30 set during the first 3 postreversal 
min and thereafter at 5, 10, 20, and 30 min. Platelet 
counts and white blood cell counts, using a hand hemo- 
cytometer, were determined at baseline, 3 min after pre- 
treatment, immediately prior to protamine administra- 
tion, and thereafter at 3, 5, and 30 min postreversal. 
Adequate anticoagulation and its reversal were docu- 
mented by measuring activated clotting times (ACT, 
Hemochron, Edison, NJ). 
Prostacyclin was measured as its stable metabolic deg- 
radation product, 6-keto-PGF,,, and thromboxane was 
measured as its stable degradation product, TxB,. These 
prostanoids were measured at baseline, 3 min following 
completion of pretreatment, immediately prior to prot- 
amine administration, and at 1,3, and 30 min postrever- 
sal. Assays were undertaken in aortic, femoral venous, 
and left atria1 blood samples, the latter reflecting pulmo- 
nary blood. Prostacyclin was determined by RIA with a 
tritiated-labeled tracer (New England Nuclear, Boston, 
MA) having limited cross-reactivity with other prosta- 
glandins (PGE,, 2.5%; PGF,,, 0.3%; PGE,, 0.2%; 
PGF,,, 0.05%; and TxB,, ~0.3%). Thromboxane was 
also measured with RIA using a tritiated tracer, having 
little cross-reactivity with other prostaglandins (PGD,, 
1.0%; PGD,, 0.32%; PGF,,, 0.04%; and PGF,,, 0.04%). 
Prostanoid assays were performed in duplicate. 
To determine if elevations in prostacyclin levels after 
protamine observed in the present study resulted from 
the protamine administration alone, or from the accom- 
panying hypotensive response, another group of 8 ani- 
mals was studied. They were monitored in the exact 
same fashion as the previous 24 dogs with the adminis- 
tration of nitroprusside at an infusion rate producing a 
hypotensive response parallel to that produced by prot- 
amine reversal of heparin. Prostacyclin and thrombox- 
ane levels were measured in these dogs. These animals 
were not given heparin or protamine, only nitroprusside. 
Platelet aggregation studies were conducted in all 
study groups before and after pretreatment. Platelet- 
rich plasma (PRP) was prepared by centrifugation of 
venous blood at 2OOg for 10 min, and platelet-poor 
plasma (PPP) was prepared by centrifugation of the su- 
pernatant at 1OOOg for an additional 10 min. PRP (450 
~1) was then stimulated by addition of 2 X 10e5 M ADP, 
and aggregation was observed after a 3-min period in a 
platelet aggregometer (Sienco, Turkey Creek, CO), with 
PRP considered as 0% transmission and PPP as 100% 
transmission. Platelet aggregation measurements were 
made in duplicate. 
Animal care complied with the Principles of Labora- 
tory Animal Care and the Guide for the Care and Use of 
Laboratory Animals (NIH Publication No. 80-23, revised 
1985). Statistical analyses included ANOVA and un- 
paired two-tailed t tests for parametric data, Kruskal- 
Wallis and Wilcoxon’s rank sum for nonparametric 
data, and correlation statistics when appropriate. 
RESULTS 
Baseline values for blood pressure, heart rate, and pul- 
monary artery pressures were statistically similar be- 
tween the three groups indicative of steady-state condi- 
tions at the time of the protamine administration with 
no adverse influence by the saline, U63,557A, or indo- 
methacin. Significant differences in blood pressure be- 
tween the three groups were noted from 75 set to 10 min 
following protamine administration (Fig. 2). Group III 
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FIG. 2. Changes in blood pressure in three groups. 
indomethacin-pretreated dogs attenuated the hypoten- 
sive response, when compared to Group II U63,557A 
pretreated dogs (P < O.Ol), with maximum declines of 
-8 + 27 and -56 + 24 mm Hg occurring in these two 
groups, respectively, and a -23 -f 33 mm Hg decline oc- 
curring in Group I control dogs. Heart rate differences 
were noted at 90, 120, and 150 to 165 set and at 5 and 10 
min postreversal (Fig. 3), with maximum declines being 
significantly less in Group III indomethacin-pretreated 
animals (-9 k 17 beats/min) compared to Group II 
U63,557A-pretreated dogs (-30 +- 29 beats/min). Group 
differences in pulmonary artery systolic pressure oc- 
curred 165 set to 10 min postreversal, and differences in 
pulmonary artery diastolic pressure occurred 75 set to 10 
min postreversal. Although increases in pulmonary ar- 
tery diastolic pressures affected Group I control dogs, 
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FIG. 3. Changes in heart rate in three groups. 
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FIG. 4. Changes in cardiac output in three groups. 
changes in pulmonary artery diastolic pressures were 
minimal in Group III indomethacin-pretreated dogs 
with actual declines in Group II U63,557A-pretreated 
dogs. Maximum declines in cardiac output (Fig. 4) were 
less pronounced in indomethacin pretreated Group III 
dogs (-12 k 20%) compared to Group I control dogs 
(-18 + 24%) or U63,557A-pretreated Group II dogs 
(-39 f 32%). Differences between groups, by Kruskal- 
Wallis analysis, occurred 165 to 180 set and 10 min 
postreversal. Similarly, more severe declines in carotid 
artery flow occurred with Group II U63,557A pretreat- 
ment (-26 +- 27%) compared to Group I controls (-14 
+ 26%) or Group III indomethacin pretreatment (-14 
+. 28%). 
Systemic mixed venous oxygen saturations differed at 
30,120, and 150 set to 10 min postreversal, being statis- 
tically different between Groups I and II (P < 0.05) and 
Groups II and III (P -C 0.05). Maximal declines were -3 
_t 8% in Group III indomethacin-pretreated dogs, -4 
f 6% in Group I control dogs, and -18 2 19% in Group 
II U63,557A-pretreated dogs. Jugular venous oxygen sat- 
urations were also different between groups at 120 set 
and at 10 and 20 min postreversal. No differences in 
systemic arterial oxygen saturations were observed be- 
tween these groups. 
Systemic oxygen consumption, although not statisti- 
cally different among pretreatment groups (Fig. 5), ex- 
hibited greater declines in Group II animals receiving 
U63,557A (-36 f 29%, 75 to 90 set postreversal) than in 
Group I control dogs (-17 + 24%, 105 to 120 set postre- 
versal) or Group III dogs pretreated with indomethacin 
(-15 -t 22%, 75 to 90 set postreversal). On the contrary, 
although not statistically different, maximum declines 
in cerebral oxygen consumption (Fig. 5) in Group I ani- 
mals of -32 f 40% and Group III dogs of -25 +- 24% 
were not matched by similar declines in Group II dogs 
receiving U63,557A, where actual increases were ob- 
served. 
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FIG. 5. Changes in systemic oxygen consumption and cerebral 
oxygen consumption in three groups. 
Platelet count declines were pronounced in all groups, 
with maximum declines of -54 + 21% in Group I control 
dogs, -55 f 10% in Group II U63,557A-pretreated ani- 
mals, and -52 + 18% in Group III indomethacin-pre- 
treated dogs. White blood cell declines were more 
marked with Group II U63,557A pretreatment (-40 
f 15%) than in Group I controls (-7 + 27%) or with 
Group III indomethacin pretreatment (-27 + 18%). 
Prostacyclin (Fig. 6) and thromboxane (Fig. 7) levels 
were significantly different in the study groups. Three 
minutes following pretreatment, prostacyclin levels fell 
most with Group III indomethacin pretreatment (-35 
f 24, -45 +- 18, and -41 + 18% within aortic, venous, 
and pulmonary samples, respectively), compared to simi- 
lar measurements in Group I controls (-9 f 10, -7 -+ 23, 
and -13 f 15%) and with Group II U63,557A pretreat- 
ment (+48 + 20, +46 + 31, and +46 f 45%). One minute 
after protamine reversal, Group III indomethacin pre- 
treated dogs exhibited less prostacyclin elevations in 
aortic and pulmonary samples than in Group I or II ani- 
mals (P < 0.05) with actual declines observed in Group 
III. Maximal elevation in prostacyclin of +576 f 1264% 
was found in Group II aortic blood. Group III indometh- 
acin pretreatment, in comparison to Group I or II, re- 
sulted in significantly less elevation in prostacyclin 3 
min after protamine reversal within venous and pulmo- 
nary samples (P < 0.05), whereas at 30 min, differences 
occurred in all samples (aortic, venous, and pulmonary) 
between Group III indomethacin-pretreated dogs and 
Group I and II dogs (P < 0.05), with declines in prosta- 
cyclin in Group III animals. 
Thromboxane levels 3 min after pretreatment de- 
clined most with Group III indomethacin pretreatment, 
were slightly less in Group II U63,557A-pretreated ani- 
mals, and were elevated in Group I controls. Significant 
group differences in TxB, were noted only in venous 
samples at 1,3, and 30 min postreversal (P < 0.05), with 
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FIG. 6. Prostacyclin levels in aortic, venous, and pulmonary 
blood. 
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FIG. ‘7. Thromboxane levels in aortic, venous, and pulmonary 
blood. 
ring in Group I controls 3 min postreversal, in contrast 
to a -11 + 19% decline in Group II U63,557A-pretreated 
dogs (P < 0.01) and a -20 f 16% decline in Group III 
indomethacin-pretreated dogs (P -c 0.01). 
Elevations of prostacyclin in aortic, venous, and pul- 
monary samples correlated well with declines in blood 
pressure at 1 min after protamine administration (r 
= 0.53, 0.52, and 0.53, respectively; P G O.Ol), as well as 
at 3 min postreversal (r = 0.53,0.70,0.60, respectively; P 
< 0.01). No significant correlations were found 30 min 
postreversal. No correlation existed between thrombox- 
ane elevations and declines in blood pressure. Correla- 
tions between prostacyclin elevations and oxygen con- 
sumption declines were found to be significant only in 
aortic and venous samples 3 min postreversal (r = 0.46, 
0.43; P < 0.05). No significant correlations existed be- 
tween thromboxane elevations and oxygen consump- 
tion. Changes in thromboxane and prostacyclin activity 
were not correlated with cerebral oxygen consumption 
changes. Finally, correlations between prostacyclin ele- 
vations and reductions in pulmonary artery systolic or 
diastolic pressures occurred at all time periods, whereas 
only one isolated correlation between thromboxane and 
elevations in pulmonary artery diastolic pressure oc- 
curred in venous blood 3 min postreversal (r = 0.48; P 
< 0.05). 
Platelet aggregation revealed a 10% decline in Group I 
control animals between the baseline sample and the 
sample obtained following pretreatment (15.9 to 14.3%), 
a 40% decline in Group II dogs receiving U63,557A (13.9 
to 8.4%), and a 32% decrease in Group III animals re- 
ceiving indomethacin (14.7 to 10%). Baseline aggrega- 
tion values were low, perhaps being an effect of the so- 
dium pentobarbital anesthetic [4]. 
The 8 animals given nitroprusside exhibited a -65 
mm Hg drop in blood pressure 3 min after infusion of 
this agent began. Declines in prostacyclin were observed 
at 1, 3, and 30 min in aortic, venous, and pulmonary 
samples, but no significant correlations between de- 
clines in blood pressure and changes in prostacyclin lev- 
els were evident. This suggests that hypotension itself 
cannot explain the prostacyclin elevations. In these 
same animals, thromboxane levels were elevated after 
nitroprusside administration, but did not correlate with 
blood pressure changes. 
DISCUSSION 
Protamine reversal of heparin anticoagulation typi- 
cally causes potentially adverse hemodynamic and hema- 
tologic responses, including vasodilation and hypo- 
tension, bradycardia, pulmonary artery hypertension 
or hypotension, thrombocytopenia, and leukopenia. 
Clinically, significant systemic arterial hypotension and 
pulmonary artery hypertension have been noted in 4% 
of cases and nearly 100 deaths have been attributed to 
the use of protamine [3,5,6]. Initial vasodilation occur- 
ring after protamine is manifested by a fall in systemic 
vascular resistance [ 71. During this early period of vaso- 
dilation, cardiac output increases in a compensatory 
fashion. However, approximately 60 set after vasodila- 
tion begins, cardiac output and oxygen consumption fall, 
suggesting a more direct central effect of protamine [8]. 
Several investigations, including recent work from our 
laboratory using an isolated rabbit heart model, suggest 
that protamine may produce direct dose-dependent de- 
pression of myocardial contraction [g-14]. However, few 
studies have addressed the mechanism for protamine- 
induced vasodilation and hypotension. The present in- 
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vestigation strongly supports the tenet that prostacyclin 
generation is associated with the hypotensive and vaso- 
dilatory effects of protamine administration. 
The nature of changes in arachidonic acid pathway 
metabolites during protamine reversal of heparin has 
been examined by others. In a porcine experimental 
model, at the conclusion of a 3-min protamine infusion 
(2 mg/kg), there was a 35 mm Hg drop in mean arterial 
blood pressure, an increase in mean pulmonary artery 
pressure of 17 mm Hg, a decrease in left ventricular end 
diastolic pressure, and a concomitant decrease in arte- 
rial and mixed venous PO, [ 11. At the same time, throm- 
boxane levels increased 460%, prostacyclin levels in- 
creased X0%, and prostaglandin F,, levels increased 
220%, with its major degradation product 13-14-dihy- 
dro-15-keto prostaglandin F,, (KH, PGF,,) increasing 
690%. There was little difference in arterial and mixed 
venous plasma prostanoid activities. In this same study, 
indomethacin (10 mg/kg), given intravenously before ad- 
ministration of heparin and protamine, blocked these 
changes with no evidence of hypotension, pulmonary ar- 
tery hypertension, blood gas changes, or prostanoid ele- 
vation. These former investigators concluded that acti- 
vation of the arachidonic acid cascade occurs in the 
lungs, that the increased pulmonary vascular resistance 
can best be explained by liberation of the vasoconstrict- 
ing prostanoids TxA, and PGF,, , and that prostacyclin 
may be partially responsible for the low systemic vascu- 
lar resistance noted. 
Conzen and associates studied the TxA, receptor an- 
tagonist BM 13.177 (10 mg/kg) infused 5 min before 
protamine administration and indomethacin (10 mg/kg) 
given before heparin and protamine [2]. In the group 
given BM 13.177, levels of TxB, and PGF,, remained 
similarly elevated after protamine as in control pigs, but 
significant hemodynamic alterations were not observed. 
In fact, a 21% decline in pulmonary vascular resistance 
occurred 5 min after the completion of the protamine 
infusion. No hemodynamic changes or alterations in 
plasma prostanoid levels occurred after protamine ad- 
ministration in animals pretreated with indomethacin. 
These authors concluded that most of the adverse hemo- 
dynamic effects associated with protamine were me- 
diated by TxA,. However, the model utilized produced 
little hypotension with at most an 11% decrease in mean 
arterial blood pressure 5 min after the termination of 
protamine infusion. This would not have represented 
significant hypotension as reflected in our study by 
maximum changes of -45% in Group II U63,557A- 
treated dogs and -21% in control animals. Such differ- 
ences most likely relate to species differences. The slight 
decreases in pulmonary artery pressure and pulmonary 
vascular resistance in these pigs pretreated with BM 
13.177 were thought likely to be related to increased pro- 
duction of prostacyclin, as evident by the 102% increase 
in 6-keto-PGF,, in this group compared to the 63% in- 
crease in control animals 2 min after protamine adminis- 
tration. 
Pulmonary artery vasoconstriction and hypertension 
have been associated with thromboxane elevations in 
pigs, awake sheep, and patients during protamine rever- 
sal of heparin anticoagulation [3,15,16]. Although plate- 
let sequestration with release of vasoactive agents may 
play a role in the generation of thromboxane [ 171, plate- 
lets are not necessary for the pulmonary responses. This 
has been documented in studies involving a rodent pul- 
monary vascular injury model using protamine in cell- 
and plasma-free solutions [ 181, in pigs using protamine 
in dextran perfusions [ 191, in isolated dextran-perfused 
cat lung preparations [20], and in sheep having platelet 
depletion by antibody administration [21]. In the 
current study the lessening of pulmonary systolic and 
diastolic hypertension that followed U63,557A pretreat- 
ment supports the importance of thromboxane in the 
pulmonary response. In addition, the fact that all three 
groups of animals in our study exhibited similar pro- 
found declines in platelet counts suggests that platelet 
sequestration occurs from a direct effect of protamine 
rather than through an arachadonic acid-mediated 
mechanism, as has been suggested previously [ 221. 
The pulmonary effects and the systemic hypotensive 
response are often separate and distinct, as has been 
noted by the blocking of the pulmonary hypertensive 
response but not the systemic fall in blood pressure with 
acetysalicylic acid and iloprost [23, 241. Data from the 
current investigation indicate that systemic hypoten- 
sion and vasodilation relate to prostacyclin generation 
and not to thromboxane production. Dogs pretreated 
with the thromboxane synthetase inhibitor U63,557A 
exhibited the most pronounced hemodynamic changes, 
suggesting that PGG,/PGH, may shunt toward produc- 
tion of more prostacyclin or PGD,, which is another po- 
tent vasodilator and platelet inhibitor [25-311. It is be- 
lieved that this process occurs in contiguous tissues, by 
the isomerase activity of plasma albumin, or from leuko- 
cyte production, respectively, leading to an increased 
load of vasodilator prostaglandins. In fact, 3 min after 
infusion of U63,557A, prostacyclin levels were increased 
48, 46, and 46% in artery, vein, and pulmonary blood 
samples, respectively, in contrast to decreases of -35, 
-45, and -41% in the same blood samples after indo- 
methacin pretreatment. The strong statistical correla- 
tions between prostacyclin elevations and blood pres- 
sure declines at 1 and 3 min after protamine administra- 
tion support the probable existence of prostanoid 
shunting in this setting. 
During thromboxane synthetase inhibition, the endo- 
peroxide precursors PGG, and PGH, may occupy and 
activate the thromboxane receptor [32]. Using the 
thromboxane receptor antagonist SQ 29,548 (Squibb, 
Princeton, NJ), we observed no inhibition in the magni- 
WAKEFIELD ET AL.: PROSTACYCLIN AND PROTAMINE 455 
tude of protamine sulfate-induced adverse hemody- 
namic responses in the same canine model used in the 
current investigation (unpublished observations). This 11. 
lends further credence to our conclusion that thrombox- 
ane is not the major mediator of protamine-induced hy- 
potension and vasodilation. 
12. 
Protamine causes declines in oxygen consumption 
both in uiuo [8] and in vitro [33], most likely because of 13. 
its polycationic character [18]. One would not expect 
either U63,557A or indomethacin pretreatment to com- 
pletely block these metabolic changes. Indomethacin 14. 
pretreatment did attenuate to some degree the decline in 
systemic oxygen consumption, suggesting that a portion 
of the decline in oxygen consumption is related to its 15. 
hemodynamic effect rather than to its metabolic effect, 
as has been shown previously [24]. However, it is clear 
that the decline in oxygen consumption relates in part to 1s. 
direct metabolic toxic effects of the drug on cellular ele- 
ments and is unrelated to systemic hypotension, vasodi- 
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